Effective viral disease chemotherapy has become increasingly feasible in recent years as a result of extensive screening studies and the apparent success of clinical trials with a few select compounds. The chemotherapy approach to viral disease control is of particular interest, since the most desirable alternative to this control, vaccination, is wholly effective only if the vaccines are used by the majority of a specific human population, and is ineffective if the disease to be controlled is caused by a broad spectrum of agents, such as is the case for the common cold. Because of the potential of antiviral chemotherapy, we have carried out a series of studies to evaluate the in vivo antiviral activity of a number of compounds. The compounds used were selected especially for their known biological activity in one or more in vivo tumor systems or their activity in vitro or in vivo in animal-virus systems, or because of their apparent chemical relationship to biologically active compounds. Viral agents used in these studies included Friend leukemia virus, Rous sarcoma virus, mouse salivary gland virus, influenza virus, vaccinia virus, and rabbitpox virus. In a previous communication (22) , the results of studies with the Friend leukemia virus were described. The present report concerns the results of investigations with influenza, vaccinia, and rabbitpox viruses.
MATERIALS AND METHODS
Inifluentza virus. The strains of influenza virus used for primary screening experiments were the PR8 strain of influenza A virus (PR8) or the Japan 305 strain of Asian influenza virus (Asian). In certain follow-up studies, the Lee strain of influenza B virus (Lee) The initial criteria for evaluation of anti-influenza virus activity of each drug were increases in the time of mean survival and in the number of survivors 21 days after virus inoculation. Comparative experiments carried out during these studies indicated that the reduction of virus-induced lung consolidation of drug-treated animals on the 10th day after virus inoculation was an equally sensitive procedure and had the advantage of requiring less time. The former procedure was therefore used in approximately two-thirds of the experiments and the latter method was used in the remainder of the studies.
The results of the experiments in which the first procedure was used were statistically evaluated by comparing (by means of the t test) the mean survival time of drug-treated, virus-infected animals dying on or before day 21 with the mean survival time of the virus control animals. If the P value obtained was <0.05 but >0.001, the antiviral activity was considered questionable. If the P value was <0.001, the drug was considered to have possible antiviral activity. The data were questionable if a significant increase in mean survival time occurred in animals treated with low dosages of the drug, but did not occur in animals treated with higher nontoxic concentrations.
The same consideration applied if activity was observed in mice infected with a high level of virus but not in those infected with lower virus doses. The number of surviving infected, treated animals was compared with the number of virus control mice surviving (if any) by means of the chi-square analysis technique. If the P values calculated by this method were <0.3 but >0.05 (approximate standard error), the antiviral activity was questionable, whereas values of <0.05 were indicative of possible antiviral activity.
The evaluation of antiviral activity on the basis of reduction of virus-induced lung consolidation was carried out by scoring each lung on a "blind" basis, i.e., the scorers did not know the history of the donors of the lungs. The lungs were graded according to the following scale: 5 = death with consolidation, 4 = 100% consolidation, 3 = -75% consolidation, 2 = -50% consolidation, 1 = -25% consolidation, 0 = no consolidation. An average lung consolidation score was calculated by dividing the total grade of consolidation by the number of lungs graded. The data were statistically evaluated using White's modification of the Wilcoxon test (28 ul 00 00 00 00 00 00 00 00 00 00 00
-. Ir- Two compounds were considered active against influenza virus. These were amantadine hydrochloride (NSC 83653) and DL-noformicin (NSC 72942). The results of the death-pattern experiments with these two compounds are summarized in Table 2 , and the results of lung consolidation experiments with these compounds are indicated in Table 3 . DL-Noformicin was tested against the PR8 virus by means of reduction in hemagglutination (HA) titers in lung suspensions of treated, infected mice as an additional criterion for evaluation. The results of this experiment are shown in Table 4 . The methods of Ginsberg and Horsfall (8) , and modifications of these methods as indicated in Table 4 , were used to determine the HA titers. Marked reductions in HA titers were observed after treatment in this experiment, indicating that therapy with DL-noformicin reduced the virus titer in the lungs of the infected mice. Neither amantadine hydrochloride nor DL-noformicin was considered active in every test carried out, although the activity was reproducible when identical viruses and treatment schedules were used in confirming experiments. The former compound was more active against the Asian virus than against the PR8 virus, and was usually more effective when administered by a treatment schedule beginning prior to virus inoculation. DL-Noformicin was active in one or more experiments against all the influenza viruses tested and when used in a variety of treatment schedules, including intraperitoneal administration in a single injection 24 -Compounds were considered active if treatment of virus-infected mice resulted in dose-responsive significant increases in mean survival time or in number of survivors. 6 ICR Swiss mice were inoculated intranasally with 0.06 ml of influenza virus; 8-to 10-g mice were used unless otherwise indicated.
c Viruses: see footnote g, Table 1 . d Treatment schedules: see footnote e, Table 1 . e P = probability that any increase in the number of survivors in the virus-infected, treated groups compared to the virus control group was due to chance, as determined by chi-square analysis. P < 0.3 = significant, P < 0.05 = highly significant. f P = probability that any observed increase in mean survival time of virus-infected, treated groups compared to the virus-control group was due to chance, as determined by t test. P < 0.05 = significant, P < 0.001 = highly significant. o In these instances, 18 b ICR Swiss mice were inoculated intranasally with 0.06 ml of influenza virus; 8-to 10-g mice were used unless otherwise indicated.
c Virus: see footnote g, Table 1 . d Treatment schedules: see footnote e, Table 1 . P p = probability that any observed increase in number of survivors in the virus-infected, treated groups compared to the virus-control group was due to chance. Determined by chi-square analysis.
f Lung consolidation score: total grade of consolidation/number of animals. Lungs were graded according to the following scale: 5 = death with consolidation; 4 = 100% consolidation; 3 = -75% consolidation; 2 = -50% consolidation; 1 = -25% consolidation; 0 = no consolidation. a P = probability that decrease in lung consolidation score of drug-treated, infected animals compared to the virus-control group was due to chance. Determined by White's modification of the Wilcoxon test.
h In these instances, 18 -to 21-g mice were used.
lished describing the anti-influenza virus activity of amantadine hydrochloride. These reports have generally indicated that this drug is most effective when administered prophylactically against the Asian influenza virus. Our studies confirm these observations, although the antiviral activity of the compound was not spectacular in any experiment.
DL-Noformicin was originally reported to be active against the influenza virus by McClelland (14) , and by Schabel and Skipper (20) in separate investigations. Our experiments indicate that the compound is active to a degree against the PR8, Asian, and Lee influenza viruses, but, as was the case for amantadine hydrochloride, this activity was not considered marked in any experiment. In the original reports, the noformicin used was produced biosynthetically by Nocardia formica. The material used in the present experiments, however, was chemically synthesized, and a definite difference between the in vivo toxicity of the synthetic compound and the recorded toxicity of the naturally occurring material has been observed. These data suggest that a chemical difference exists between the natural and synthetic products. None of the original natural product was available for the present studies, so concomitant comparisons could not be made. DLNoformicin had a greater degree of antiviral activity, that is, a higher therapeutic index (25) , when large mice were used. We have found that the large (18 to 21 g) mice will apparently tolerate up to four times the amount of drug per unit weight that the small (8 to 10 g) mice can be given; hence, if the drug has a low therapeutic index, and is consequently active only at a nearly toxic dose, this activity may be masked by using the smaller animals. Because of this observation, all compounds in these influenza virus studies which had a suggestion of antiviral activity when tested in the small mice were retested in the larger animals. With the exception of DL-noformicin, no consistent antiviral activity of significance was observed. Treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC 409962) resulted in slight increases in the life span of PR8-infected mice, as we reported previously (21), but these increases were not statistically significant.
The vaccinia virus chemotherapy experiments confirmed the reported in vivo antiviral activity of isatin-fl-thiosemicarbazone (2, 27), 5-iodo-2'-deoxyuridine (12) , N-methylisatin-,B-thiosemi-SIDWELL ET AL. c Lungs were homogenized in phosphate-buffered saline (PBS) centrifuged at low speed, and twofold dilutions of the supernatant fluid were mixed with the appropriate red blood cells (RBC). The supernatant fluid and RBC were incubated at room temperature for up to 2 hr, and the degree of hemagglutination was determined by the sedimentation pattern. d Lungs were homogenized in phosphate-buffered saline, treated with receptor-destroying enzyme (RDE) for 2 hr at 37 C, centrifuged at low speed, and twofold dilutions of the supernatant fluid were made in 2.5% sodium citrate. Each dilution was then mixed with the appropriate RBC (suspended in PBS), incubated and the degree of hemagglutination determined as in test 1.
e Lungs were homogenized in PBS, treated with RDE for 16 hr at 20 C and 2 hr at 37 C, centrifuged at low speed, and twofold dilutions of the supernatant fluid were made in 2.5% sodium citrate. Each dilution was then mixed with the appropriate RBC (suspended in 2.5% sodium citrate), incubated, and the degree of hemagglutination determined as in test 1. This method was similar to that described by Ginsberg and Horsfall (8) .
carbazone (2, 27) and 5-(2,4-dichlorophenoxy)-2-thiouracil (1, 15, 26) . 9-f3-D-Arabinofuranosyladenine reportedly has antivaccinia virus activity in vitro (6, 7) , but our studies are the first to demonstrate that the compound has marked in vivo activity against this virus. We consider the in vivo activity of this compound to be approximately equivalent to the antiviral activity of isatin-,3-thiosemicarbazone. None of the other compounds listed in Table 5 The supply of 5-(mercaptomethyl)uracil was sufficient to carry out a single experiment only, but the activity observed was dose-responsive. Treatment of vaccinia virus-infected mice with a cortisone derivative, 9-a-fluoro-2a-methylhydrocortisone 21-acetate, was effective in prolonging the mean survival time. This observation was interesting, since a number of reports (3, 9, 16) indicated that cortisone treatment usually enhances the infectious process.
5-Iodo-2'-deoxyuridine is known to be active against herpes and vaccinia viruses, both deoxyribonucleic acid agents in animals (11, 12) . In our studies, the drug was apparently inactive against vaccinia virus infections in mice inoculated with the virus by the intracerebral route, but was effective in prolonging the mean survival time if the mice were inoculated with the virus by the intranasal route. These data suggest that this drug does not cross the blood-brain barrier, but is effective against infections in other parts of the body. In contrast, isatin-4-thiosemicarbazone and cytovirin were apparently less active against the intranasally inoculated agent. Streptonigrin, N-methylisatin ,B-thiosemicarbazone, and 5 (2,4- 
